Symbol | Exchange | Currency |
|---|
April 7 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE- COHORT REVIEW COMMITTEE CONFIRMED PHASE I CLINICAL TRIAL OF PD1-VAXX, WILL PROCEED TO THIRD AND FINAL HIGHEST DOSE COHORT
Nov 2 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE RECEIVES FDA IND APPROVAL FOR PD1-VAXX TRIAL IN USA* U.S. FDA APPROVAL ALLOWS CO TO INITIATE RECRUITMENT, DOSING IN USA PHASE I...
Sept 9 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE LTD - SECURES $5.7 MILLION OPTION UNDERWRITING AGREEMENT
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Buy | Sell | Strong Sell | Strong Sell | Buy |
| Summary | Buy | Sell | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.62 | 8.44 | 7.45 | -0.620 | -7.52% | 8.39M | Sydney | |||
| 32.15 | 32.95 | 32.03 | -0.95 | -2.87% | 539.86K | Sydney | |||
| 7.20 | 7.98 | 7.16 | -0.780 | -9.77% | 3.90M | Sydney | |||
| 0.40 | 0.00 | 0.00 | +0.010 | +2.56% | 743.67K | Sydney | |||
| 0.41 | 0.00 | 0.00 | -0.025 | -5.75% | 421.86K | Sydney | |||
| 3.28 | 3.31 | 3.27 | 0.00 | 0.00% | 341.77K | Sydney | |||
| 95.45 | 97.15 | 93.87 | -1.990 | -2.04% | 4.13M | Sydney | |||
| 0.37 | 0.00 | 0.00 | -0.09 | -19.57% | 6.17M | Sydney | |||
| 0.86 | 0.00 | 0.00 | +0.010 | +1.18% | 1.75M | Sydney | |||
| 2.72 | 2.78 | 2.66 | -0.080 | -2.86% | 1.12M | Sydney | |||
| 19.50 | 20.59 | 19.26 | -1.020 | -4.97% | 14.32M | Sydney | |||
| 27.35 | 27.88 | 27.03 | -0.820 | -2.91% | 9.46M | Sydney | |||
| 29.01 | 29.88 | 28.77 | -0.79 | -2.65% | 839.78K | Sydney | |||
| 81.71 | 83.77 | 80.79 | -2.06 | -2.46% | 717.94K | Sydney | |||
| 10.81 | 10.86 | 10.65 | -0.10 | -0.92% | 570.98K | Sydney |